NO20083715L - Antistoffer mot human IL-22 og anvendelser derav - Google Patents

Antistoffer mot human IL-22 og anvendelser derav

Info

Publication number
NO20083715L
NO20083715L NO20083715A NO20083715A NO20083715L NO 20083715 L NO20083715 L NO 20083715L NO 20083715 A NO20083715 A NO 20083715A NO 20083715 A NO20083715 A NO 20083715A NO 20083715 L NO20083715 L NO 20083715L
Authority
NO
Norway
Prior art keywords
disorders
antibodies
antibodies against
against human
allergies
Prior art date
Application number
NO20083715A
Other languages
English (en)
Norwegian (no)
Inventor
Geertruida M Veldman
Jing Li
Davinder Singh Gill
Lynette A Fouser
Viia Valge-Archer
David C Lowe
Caroline S Russell
Suzanne E Cohen
Albert B Thom
Ralph R Minter
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38236225&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20083715(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of NO20083715L publication Critical patent/NO20083715L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO20083715A 2006-02-21 2008-08-28 Antistoffer mot human IL-22 og anvendelser derav NO20083715L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77459606P 2006-02-21 2006-02-21
PCT/US2007/004430 WO2007098170A1 (en) 2006-02-21 2007-02-21 Antibodies against human il-22 and uses therefor

Publications (1)

Publication Number Publication Date
NO20083715L true NO20083715L (no) 2008-11-06

Family

ID=38236225

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083715A NO20083715L (no) 2006-02-21 2008-08-28 Antistoffer mot human IL-22 og anvendelser derav

Country Status (31)

Country Link
US (4) US7901684B2 (de)
EP (3) EP1991584B1 (de)
JP (1) JP5150516B2 (de)
KR (2) KR20080113214A (de)
CN (1) CN101426816B (de)
AR (1) AR059604A1 (de)
AT (1) ATE538137T1 (de)
AU (1) AU2007217751B2 (de)
BR (1) BRPI0708101B8 (de)
CA (1) CA2643226C (de)
CR (1) CR10237A (de)
DK (2) DK3020729T3 (de)
EC (1) ECSP088751A (de)
ES (2) ES2738731T3 (de)
HN (1) HN2008001292A (de)
HU (1) HUE044595T2 (de)
IL (1) IL193605A (de)
MX (2) MX2008010708A (de)
MY (1) MY146664A (de)
NO (1) NO20083715L (de)
NZ (1) NZ570878A (de)
PE (1) PE20080111A1 (de)
PL (2) PL3020729T3 (de)
PT (2) PT1991584E (de)
RU (1) RU2467016C2 (de)
SA (1) SA07280062B1 (de)
SG (1) SG172628A1 (de)
SI (2) SI1991584T1 (de)
TW (1) TWI417301B (de)
WO (1) WO2007098170A1 (de)
ZA (1) ZA200807278B (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0010097A (pt) * 1999-04-28 2002-02-13 Genetics Inst Polinucleotìdeo isolado; célula hospedeira; processo para a produção de uma proteìna codificada pelo polinucleotìdeo; proteìna; composição; e; anticorpo
EP1954719A2 (de) 2005-12-02 2008-08-13 Genentech Inc. Zusammensetzungen und verfahren zur behandlung von krankheiten und leiden in zusammenhang mit zytokin-signalisierung sowie unter verwendung an il-22 und il-22r bindender antikörper
TWI417301B (zh) * 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
US20110159011A1 (en) * 2008-08-28 2011-06-30 Wyeth Llc Uses of il-22, il-17, and il-1 family cytokines in autoimmune diseases
US9506919B2 (en) 2009-04-13 2016-11-29 The Board Of Trustees Of The Leland Stanford Junior University Methods and devices for detecting the presence of an analyte in a sample
AU2010291985B2 (en) 2009-09-14 2016-05-05 The Regents Of The University Of Colorado Modulation of yeast-based immunotherapy products and responses
JP5937019B2 (ja) * 2010-03-12 2016-06-22 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 磁気センサに基づく結合反応速度の定量的な分析
WO2011139974A2 (en) * 2010-05-03 2011-11-10 Abbott Laboratories Anti-pai-1 antibodies and methods of use thereof
CN103382223B (zh) * 2012-04-01 2015-06-10 上海益杰生物技术有限公司 针对表皮生长因子受体隐蔽表位和t细胞抗原的多功能抗体多肽
US9221904B2 (en) * 2012-07-19 2015-12-29 National Cheng Kung University Treatment of osteoarthritis using IL-20 antagonists
IN2015DN00140A (de) * 2012-08-31 2015-06-12 Argen X Bv
EP3385277A1 (de) 2013-03-15 2018-10-10 F. Hoffmann-La Roche AG Il-22-polypeptide und il-22-fc-fusionsproteine sowie verfahren zur verwendung
CN105139918B (zh) * 2015-06-26 2017-04-12 哈尔滨工业大学 一种柔板印刷用低银高性能导电浆料及其制备方法
CN105601739B (zh) * 2016-02-22 2019-01-18 王晨辉 一种人源化抗白介素22基因工程抗体及其应用
WO2018039107A1 (en) * 2016-08-22 2018-03-01 Medimmune, Llc Binding molecules specific for notch4 and uses thereof
US20190317098A1 (en) * 2016-11-24 2019-10-17 Huvet Bio, Inc. Composition for diagnosis of diseases
TWI797097B (zh) 2016-11-28 2023-04-01 日商中外製藥股份有限公司 包含抗原結合域與運送部分的多胜肽
WO2018097308A1 (ja) 2016-11-28 2018-05-31 中外製薬株式会社 リガンド結合活性が調整可能なリガンド結合分子
CN111630062A (zh) 2017-11-28 2020-09-04 中外制药株式会社 具有可调节的配体结合活性的配体结合分子
CN111836828B (zh) 2017-11-28 2024-12-20 中外制药株式会社 包括抗原结合结构域和运送部分的多肽
KR102536314B1 (ko) * 2018-05-23 2023-05-25 주식회사 휴벳바이오 질환의 진단용 조성물
US11834472B2 (en) * 2018-06-05 2023-12-05 Bioatla, Inc. Anti-IL-22 antibodies, antibody fragments, their immunoconjugates and uses thereof
CA3113948A1 (en) * 2018-10-11 2020-04-16 Alivio Therapeutics, Inc. Non-injectable hydrogel formulations for smart release
KR102226826B1 (ko) * 2020-08-06 2021-03-11 주식회사 휴벳바이오 버피 코트 시료에 사용하기 위한 췌장암 진단용 조성물
WO2022122654A1 (en) 2020-12-07 2022-06-16 UCB Biopharma SRL Multi-specific antibodies and antibody combinations
US20230416357A1 (en) 2020-12-07 2023-12-28 UCB Biopharma SRL Antibodies against interleukin-22
US12454572B2 (en) 2021-03-02 2025-10-28 Dana-Farber Cancer Institute, Inc. Methods of treating anemia in myelodysplastic syndromes
WO2023110942A1 (en) 2021-12-14 2023-06-22 Charité-Universitätsmedizin Berlin Prevention of impaired fracture healing
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
EP0098110B1 (de) 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Zusammensetzung mit längerer Wirkung
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (de) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimäre Rezeptoren durch Verbindung und Expression von DNS
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
AU597574B2 (en) 1986-03-07 1990-06-07 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US6018026A (en) 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
US5750375A (en) 1988-01-22 1998-05-12 Zymogenetics, Inc. Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0436597B1 (de) 1988-09-02 1997-04-02 Protein Engineering Corporation Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8905669D0 (en) 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
US5350836A (en) 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0585287B1 (de) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Verfahren zur herstellung von spezifischen bindungspaargliedern
GB9021679D0 (en) 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
EP0575485A1 (de) 1991-03-01 1993-12-29 Dyax Corp. Verfahren zur entwicklung bindender miniproteine
DK0580737T3 (da) 1991-04-10 2004-11-01 Scripps Research Inst Heterodimere receptorbiblioteker ved anvendelse af phagemider
EP1400536A1 (de) 1991-06-14 2004-03-24 Genentech Inc. Verfahren zur Herstellung humanisierter Antikörper
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5833976A (en) 1991-08-06 1998-11-10 Schering Corporation Use of interleukin-10 (IL-10) to treat endotoxin- or superantigen-induced toxicity
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
GB9214857D0 (en) 1992-07-13 1992-08-26 Medical Res Council Human nucleic acid fragments and their use
AU701578B2 (en) 1992-08-21 1999-02-04 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US5789192A (en) 1992-12-10 1998-08-04 Schering Corporation Mammalian receptors for interleukin-10 (IL-10)
US5536637A (en) 1993-04-07 1996-07-16 Genetics Institute, Inc. Method of screening for cDNA encoding novel secreted mammalian proteins in yeast
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5674487A (en) 1994-09-28 1997-10-07 Univ Jefferson Method for treating autoimmune diseases
EP0823941A4 (de) 1995-04-28 2001-09-19 Abgenix Inc Menschliche antikörper aus xenomäusen
AU725609C (en) 1995-08-18 2002-01-03 Morphosys Ag Protein/(poly)peptide libraries
DK0929578T3 (da) 1996-02-09 2003-08-25 Abbott Lab Bermuda Ltd Humane antistoffer, der binder human TNFalfa
WO1997039772A1 (fr) 1996-04-19 1997-10-30 Chugai Seiyaku Kabushiki Kaisha Remede contre l'arthrite rhumatoide contenant un anticorps anti-il-8 comme principe actif
ES2294799T3 (es) 1996-06-27 2008-04-01 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Moleculas de anticuerpos que interactuan especificamente con el sitio activo o hendidura de una molecula diana.
US6492507B1 (en) 1996-10-23 2002-12-10 Incyte Genomics, Inc. Polynucleotides encoding human eosinophil-derived basic protein
EP1500329B1 (de) 1996-12-03 2012-03-21 Amgen Fremont Inc. Menschliche Antikörper, die ausdrücklich menschliches TNF Alpha binden
WO1998052976A1 (en) 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
US6551799B2 (en) 1999-12-07 2003-04-22 Genentech, Inc. Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
US20030032057A1 (en) 1997-08-26 2003-02-13 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2002016611A2 (en) 2000-08-24 2002-02-28 Genentech, Inc. Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
US6350892B1 (en) 1997-09-23 2002-02-26 Bristol-Myers Squibb Company Trifluoromethyl ketone analogs as selective cPLA2 inhibitors
WO1999037682A2 (en) 1998-01-23 1999-07-29 F.Hoffmann-La Roche Ag Antibodies against human il-12
CA2329274A1 (en) 1998-05-29 1999-12-02 Steven M. Ruben Interleukin-21
US20010023070A1 (en) 1998-05-29 2001-09-20 Reinhard Ebner Interleukins-21 and 22
EP1131333B1 (de) 1998-10-26 2010-06-02 Wyeth a Corporation of the State of Delaware Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
US7081528B2 (en) 1998-10-26 2006-07-25 Ludwig Institute For Cancer Research Isolated nucleic acid molecules encoding T cell derived inducible factors
US6274710B1 (en) 1998-10-26 2001-08-14 Ludwig Institute For Cancer Research Antibodies which specifically bind T Cell inducible factors (TIFs)
WO2000034317A2 (en) 1998-12-08 2000-06-15 Biovation Limited Method for reducing immunogenicity of proteins
SI2168984T1 (sl) 1999-03-25 2012-12-31 Abbott Gmbh & Co. Kg Človeška protitelesa za vezavo IL-12 in postopki izdelave
US7307161B1 (en) 1999-04-28 2007-12-11 Genetics Institute, Llc Human Gil-19/AE289 polynucleotides
US6939545B2 (en) 1999-04-28 2005-09-06 Genetics Institute, Llc Composition and method for treating inflammatory disorders
WO2000070049A2 (en) 1999-05-19 2000-11-23 Incyte Genomics, Inc. Extracellular signaling molecules
AU5047600A (en) 1999-05-27 2000-12-18 Schering Corporation Mammalian interleukin-10 homologs: il-d110 and il-d210
ATE448246T1 (de) 1999-06-15 2009-11-15 Genentech Inc Sekretierte und transmembran-polypeptide sowie nukleinsäuren zu deren kodierung
US6897292B2 (en) 1999-12-03 2005-05-24 Zymogenetics, Inc. Human cytokine receptor
DE60043944D1 (de) 1999-12-23 2010-04-15 Zymogenetics Inc Zytokin zcyt018
US20030170823A1 (en) 1999-12-23 2003-09-11 Presnell Scott R. Novel cytokine ZCYTO18
AU2001233034A1 (en) 2000-01-27 2001-08-07 American Cyanamid Company Method for preparing alpha-sulfonyl hydroxamic acid derivatives
TWI335336B (de) * 2000-02-10 2011-01-01 Abbott Gmbh & Co Kg
DE60129137D1 (de) 2000-07-27 2007-08-09 Wyeth Corp Modulierung durch il-tif/interleukin-21
US20030012788A1 (en) 2000-07-27 2003-01-16 Jean-Christophe Renauld Method for influencing kinase pathways with IL-22
US7094570B2 (en) 2003-03-11 2006-08-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode a soluble IL-TIF/IL-22 receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7638604B2 (en) 2001-02-23 2009-12-29 Genetics Institute, Llc Monoclonal antibodies against interleukin-22
MXPA03007413A (es) 2001-02-23 2003-11-18 Inst Genetics Llc Composicion y metodo para tratar enfermedades inflamatorias.
US20040058445A1 (en) 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
US20020187512A1 (en) 2001-09-10 2002-12-12 Nagem Ronaldo Alves Pinto Crystal structure of human interleukin-22
EP1546358A4 (de) * 2002-03-22 2006-06-07 Zymogenetics Inc Anti-il-tif-antikörper und verfahren zur verwendung bei entzündung
WO2003092597A2 (en) * 2002-05-01 2003-11-13 Human Genome Sciences, Inc. Antibodies that specifically bind to chemokine beta-4
US6921538B2 (en) * 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
ES2354693T3 (es) * 2003-06-23 2011-03-17 Genetics Institute, Llc Anticuerpos contra interleucina-22 y usos para ellos.
CA2612746A1 (en) 2005-07-04 2007-01-11 Samsung Electronics Co., Ltd. Position measuring system and method using wireless broadband (wibro) signal
TW200744634A (en) 2006-02-21 2007-12-16 Wyeth Corp Methods of using antibodies against human IL-22
TWI417301B (zh) 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
US8359965B2 (en) 2007-09-17 2013-01-29 Oxford J Craig Apparatus and method for broad spectrum radiation attenuation

Also Published As

Publication number Publication date
CN101426816A (zh) 2009-05-06
US8187603B2 (en) 2012-05-29
HUE044595T2 (hu) 2019-11-28
EP1991584A1 (de) 2008-11-19
JP2009531023A (ja) 2009-09-03
US8182817B2 (en) 2012-05-22
EP3020729B1 (de) 2019-06-26
DK1991584T3 (da) 2012-04-02
IL193605A (en) 2015-07-30
TWI417301B (zh) 2013-12-01
US20100184960A1 (en) 2010-07-22
BRPI0708101B8 (pt) 2021-05-25
MX337778B (es) 2016-03-18
PT1991584E (pt) 2012-02-20
US7901684B2 (en) 2011-03-08
SI3020729T1 (sl) 2019-10-30
SA07280062B1 (ar) 2012-03-13
MY146664A (en) 2012-09-14
HN2008001292A (es) 2012-02-13
IL193605A0 (en) 2011-08-01
ATE538137T1 (de) 2012-01-15
BRPI0708101B1 (pt) 2020-01-14
ECSP088751A (es) 2008-11-27
ES2738731T3 (es) 2020-01-24
RU2008134137A (ru) 2010-03-27
WO2007098170A1 (en) 2007-08-30
PL3020729T3 (pl) 2019-12-31
US20070243589A1 (en) 2007-10-18
SI1991584T1 (sl) 2012-05-31
EP3020729A1 (de) 2016-05-18
MX2008010708A (es) 2008-11-14
KR20080113214A (ko) 2008-12-29
CN101426816B (zh) 2012-12-12
CR10237A (es) 2008-11-26
KR101616712B1 (ko) 2016-04-29
AU2007217751B2 (en) 2012-08-23
PL1991584T3 (pl) 2012-05-31
PE20080111A1 (es) 2008-02-20
HK1120813A1 (en) 2009-04-09
EP2431392B1 (de) 2015-09-09
KR20140100589A (ko) 2014-08-14
PT3020729T (pt) 2019-08-06
ES2377463T3 (es) 2012-03-27
US20130005033A1 (en) 2013-01-03
CA2643226C (en) 2016-04-12
TW200801041A (en) 2008-01-01
BRPI0708101A8 (pt) 2019-01-22
AR059604A1 (es) 2008-04-16
AU2007217751A1 (en) 2007-08-30
BRPI0708101A2 (pt) 2011-05-17
EP2431392A1 (de) 2012-03-21
SG172628A1 (en) 2011-07-28
EP1991584B1 (de) 2011-12-21
CA2643226A1 (en) 2007-08-30
RU2467016C2 (ru) 2012-11-20
US8470993B2 (en) 2013-06-25
US20110275790A1 (en) 2011-11-10
ZA200807278B (en) 2009-05-27
DK3020729T3 (da) 2019-07-29
JP5150516B2 (ja) 2013-02-20
NZ570878A (en) 2011-09-30

Similar Documents

Publication Publication Date Title
NO20083715L (no) Antistoffer mot human IL-22 og anvendelser derav
NO20083697L (no) Fremgangsmater for anvendelse av antistoffer mot human IL-22
NO20054170L (no) Antistoff mot human IL-21 reseptor og anvendelser derav
NO20083712L (no) Peptider som blokkerer bindingen av IGG til FCRN
WO2007084775A3 (en) Compositions and methods for modulation of suppressor t cell activation
ATE514713T1 (de) Antikörper gegen pd-1 und ihre verwendung
NO20092671L (no) Antistoffer mot human cytomegalovirus (HCMV)
EA201101593A1 (ru) КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА
EA200801679A1 (ru) Композиции и способы применения антител к dickkopf-1 и/или -4
EA201190041A1 (ru) Человеческие аутоантитела против альфа-синуклеина
EA201000424A1 (ru) Антитела к il-23
WO2014164959A3 (en) Anti-il-33 antibodies and uses thereof
EA200800355A1 (ru) Нейтрализующие антитела человека против b7rp1
WO2014190356A3 (en) Anti-b7-h5 antibodies and their uses
EA200800812A1 (ru) Композиции антитела против cd3
WO2011094259A3 (en) Cd127 binding proteins
WO2007126439A3 (en) Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
EA201491214A1 (ru) Композиции и способы применения антител, нацеленных на фактор p
UA103916C2 (xx) Антитіло проти dkk-1$антитело против dkk-1
WO2011092593A3 (en) Hiv-1 neutralizing antibodies and uses thereof
EA201290977A1 (ru) Гуманизированные антитела к il-25
MY149448A (en) Interleukin-21 receptor binding proteins
AR072136A1 (es) Metodos de tratamiento que utilizan proteinas de union del receptor de in-terleuquina 21
WO2006086396A3 (en) Anti-il-20, anti-il-22 and anti-il-22ra antibodies and binding partners and methods of using in inflammation
CN109311988A (zh) 一种BlyS抗体及其制备方法和应用

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application
BDEC Board of appeal decision

Free format text: DISMISSAL OF THE APPLICATION FOR PATENT IS ENFORCEABLE, SEE PATENT ACT 23

Effective date: 20120910